Navigation Links
Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center
Date:10/7/2008

Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine. While many vaccines attempt to pump up the immune system to fight off a cancer, the new vaccine, Lucanix, is genetically engineered to also trick the cancer into turning off its immune system-suppressing activities.

The first patients have begun enrolling in a new clinical trial at the Moores UCSD Cancer Center testing the effectiveness of the vaccine. The trial will involve 700 patients at some 90 centers worldwide.

Current treatments for advanced lung cancer have limited effectiveness and new therapies are needed, said Lyudmila Bazhenova, M.D., director of the Lung Cancer Unit at the Moores UCSD Cancer Center and assistant clinical professor of medicine at UC San Diego School of Medicine.

"The future treatments for advanced lung cancer may involve combinations of chemotherapy and targeted agents, and possibly even biologicals such as this," she said.

Roughly 430 patients die of lung cancer every day in the United States, according to Bazhenova, making it the nation's number one killer, despite being the second most common cancer. "While breast cancer mortality has declined about 15 percent, there hasn't been much improvement in mortality in lung cancer in the past several decades," she said. According to the American Cancer Society, an estimated 215,000 new cases of lung cancer will be diagnosed, and 162,000 individuals will die from the disease this year in the United States.

The vaccine, developed by NovaRx, a biopharmaceutical company based in San Diego, consists of lung cancer cells that have been genetically altered to shut down the cancer's ability to depress the immune system. In addition, the cells are also modified to enable the immune system to see them better.

Bazhenova explained that earlier tests of the vaccine's effectiveness produced encouraging results. The current trial is for patients with stage four non-small cell lung cancer who have completed four to six cycles of platinum-based chemotherapy. Those patients who have had a response to the treatment, meaning either tumor shrinkage or stable disease, may be eligible. The trial is a double-blind, placebo-controlled study, where neither patients nor doctors know who is getting the vaccine and who may be receiving a placebo. Patients receive injections once a month for 18 months, after which they receive two quarterly injections and are treated until disease progression. The trial's main goal is to determine if the vaccine can improve patient survival compared to taking placebo.


'/>"/>

Contact: Steve Benowitz
sbenowitz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
2. Novel virus detection identifies new viruses in study of respiratory infections and asthma attacks
3. Researchers uncover novel mechanism that balances the sizes of functional areas in the brain
4. Novel Cooling Therapy May Have Aided Injured Football Player
5. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. GrantAdler Shipping Novel Implantable Vascular Access Port
8. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
9. Novel strategy under study for aggressive leukemia
10. ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
11. 454 Sequencing(TM): Science Paper Describes a Novel, Highly Efficient Method of Sequencing Ancient DNA; Sequences the Mitochondria of 10 Individual Mammoths to Prove It
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Clara, Calif. (PRWEB) , ... May 26, 2017 ... ... announces the integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware ... provides a consistent, browser-based interface for diagnostic device operations. With this platform, initializing ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, one of ... Memorial Day entertaining that are sure to satisfy your guests’ flavor cravings, while ... and cheeses featured in these refreshingly balanced recipes are packed with flavor, creating ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office ... U.S. House on May 4, would result in 23 million Americans losing their health ... the 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear ...
(Date:5/26/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... Agreements being discussed by President Donald Trump and the rest of the world. Donald ... up peace talks in the continuous battle between Israel and Palestine. The world’s eyes ...
(Date:5/26/2017)... ... 26, 2017 , ... Rob Lowe acts as host and helps educate and ... on hiking in American. Viewers can reconnect with America as it explores some of ... Many consumers have looked for an inventive new place for a family vacation, and ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
(Date:5/4/2017)... , May 4, 2017 Clarius Mobile ... wireless, handheld ultrasound scanners this week at the ... Meeting (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians ... heart rate, and evaluate pregnancy-related complications like ectopic ...
Breaking Medicine Technology: